Success Metrics

Clinical Success Rate
100.0%

Based on 30 completed trials

Completion Rate
100%(30/30)
Active Trials
1(3%)
Results Posted
53%(16 trials)

Phase Distribution

Ph phase_2
5
15%
Ph phase_3
14
42%
Ph phase_1
6
18%
Ph phase_4
2
6%
Ph early_phase_1
1
3%

Phase Distribution

7

Early Stage

5

Mid Stage

16

Late Stage

Phase Distribution28 total trials
Early Phase 1First-in-human
1(3.6%)
Phase 1Safety & dosage
6(21.4%)
Phase 2Efficacy & side effects
5(17.9%)
Phase 3Large-scale testing
14(50.0%)
Phase 4Post-market surveillance
2(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

96.8%

30 of 31 finished

Non-Completion Rate

3.2%

1 ended early

Currently Active

1

trials recruiting

Total Trials

33

all time

Status Distribution
Active(1)
Completed(30)
Terminated(1)
Other(1)

Detailed Status

Completed30
Recruiting1
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
33
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.6%)
Phase 16 (21.4%)
Phase 25 (17.9%)
Phase 314 (50.0%)
Phase 42 (7.1%)

Trials by Status

recruiting13%
withdrawn13%
unknown13%
completed3091%

Recent Activity

Clinical Trials (33)

Showing 20 of 33 trialsScroll for more
NCT05023382

A Study of Teduglutide in Japanese People With Short Bowel Syndrome

Completed
NCT06973304Phase 3

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

Recruiting
NCT03562130Phase 4

Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric Patients

Completed
NCT02949362Phase 3

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

Completed
NCT05027308Phase 3

A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or Older

Completed
NCT04832087

Pediatric Teduglutide Registry

Completed
NCT04290429Early Phase 1

Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients

Completed
NCT02431325Phase 2

A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV

Completed
NCT03596164Phase 3

An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004

Completed
NCT03953170Phase 3

Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and Complications

Withdrawn
NCT04465396Phase 1

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

Completed
NCT03422666Phase 2

Plasma Lipoprotein Response to Glucagon-like Peptide-2

Completed
NCT03442972Phase 2

Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids

Completed
NCT03268811Phase 3

A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302

Completed
NCT02980666Phase 3

Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support

Completed
NCT02889393Phase 2

Teduglutide for Enterocutaneous Fistula (ECF)

Completed
NCT03716115Phase 2

Therapeutic Approaches to Malnutrition Enteropathy

Completed
NCT00930644Phase 3

Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)

Completed
NCT01560403Phase 3

A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021

Completed
NCT01952080Phase 3

A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

Completed

Drug Details

Intervention Type
DRUG
Total Trials
33